What is it about?

Kidney transplantation has long been contraindicated in patients with atypical hemolytic uremic syndrome because of high rates of post-transplant recurrence and poor outcomes. We evaluated the impact of a pro-transplant policy, implemented in France, in patients with atypical hemolytic uremic syndrome, based on a highly individualized therapeutic strategy.

Featured Image

Why is it important?

This study demonstrates that the use of a tailored prophylactic strategy, based on new immunotherapy (eculizumab), has revolutionized transplant outcomes and the epidemiology of the disease.

Perspectives

This study lays the groundwork for further refinement in the applications of personalized medicine in patients with atypical uremic syndrome and provides very important clues to keep them off dialysis.

Julien Zuber
Paris University, Paris France

Read the Original

This page is a summary of: Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome, Journal of the American Society of Nephrology, October 2019, American Society of Nephrology,
DOI: 10.1681/asn.2019040331.
You can read the full text:

Read

Contributors

The following have contributed to this page